KYMR Kymera Therapeutics, Inc.
FY2025 10-K
Kymera Therapeutics, Inc. (KYMR) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Clinical-stage biopharma specializing in targeted protein degradation (TPD) oral small molecules for immunology and serious diseases
- • New products: Initiated Phase 2b trials for KT-621 (oral STAT6 degrader) in atopic dermatitis and asthma; Phase 1 trial started for KT-579 (oral IRF5 degrader)
Management Discussion & Analysis
- • No revenue or profitability figures disclosed in MD&A section
- • No segment performance or cash flow details provided
Risk Factors
- • Regulatory risk: FDA approval timing and success uncertainty for STAT6, IRF5, and IRAK4 programs affecting clinical development and commercialization
- • Macroeconomic risk: Potential capital exhaustion before 2029 despite $1.62B cash, risking delays in R&D and clinical trials
Financial SummaryXBRL
Revenue
$39M
Net Income
-$311M
Operating Margin
-891.1%
Net Margin
-794.0%
ROE
-19.7%
Total Assets
$1.7B
EPS (Diluted)
$-3.69
Operating Cash Flow
-$233M
Source: XBRL data from Kymera Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Kymera Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.